Hyperlipidemia associated with the use of protease inhibitors.
J H
JH
Smith
G J
GJ
Martin
C F
CF
Decker
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002784:Cholesterol / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D019888:Nelfinavir / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D019258:Saquinavir / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000378:metabolism
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D014280:Triglycerides; D019469:Indinavir; D002784:Cholesterol; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir